LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exact Sciences Corporation (“Exact” or the “Company”) (Nasdaq: EXAS).
If you purchased or otherwise acquired Exact shares, and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Exact and certain of its officers and/or directors violated federal securities laws. On May 15, 2017, Citron Research issued a report on Exact stating that “Exact Sciences pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.” Cologuard is a branded laboratory-based scan for DNA traces in stool samples, indicating colorectal cancer. Citron cited a recent report from United Healthcare, the biggest managed healthcare company in the US, that criticized the use of fecal DNA testing for colorectal cancer screening and monitoring, calling it “unproven and not medically necessary.” Citron stated that “key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.” Citron went on to say that “Poop in a box will probably be a medical dinosaur in 4 years and the value of Exact’s only asset will be 0.”
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.